Tai Ping Yang Zheng Quan·2026-03-06 00:20Investment Rating - The overall industry rating is neutral, indicating that the expected return over the next six months will be between -5% and 5% relative to the CSI 300 index [6][7]. Core Insights - The pharmaceutical sector experienced a decline of 1.12% on March 4, 2025, outperforming the CSI 300 index by 0.02 percentage points, ranking 26th among 31 sub-industries in the Shenwan classification [3]. - Notable performers in the sector included Yahui Pharmaceutical (+20.02%), Ailis (+11.17%), and Rundou Co. (+6.99%), while the worst performers were Kanghui Co. (-6.26%), Changshan Pharmaceutical (-5.89%), and Hualan Biological (-4.75%) [3]. - Priovant announced that the FDA has accepted its new drug application for Brepocitinib, granting it priority review status based on positive results from the Phase 3 VALOR study, which showed significant clinical improvement in myositis total improvement score (TIS) for the 30mg dose group [4]. Summary by Sections Market Performance - On March 4, 2025, the pharmaceutical sector's performance was -1.12%, with various sub-industries showing mixed results, including in vitro diagnostics (-0.62%) and hospitals (-0.72%) performing better than blood products (-2.16%) and offline pharmacies (-2.10%) [3]. Industry News - The FDA has accepted Priovant's application for Brepocitinib, a selective TYK2 and JAK1 dual inhibitor, which could become the first targeted therapy approved for dermatomyositis if successful [4]. - Sanyou Medical announced that its SWINGO-3D Lumbar Cage System received FDA 510(K) certification [4]. Company News - Cap Bio's subsidiary received a medical device registration certificate for its chromosome multi-STR genotyping kit [5]. - Jiukang Bio announced the approval of its blood type identification and irregular antibody screening quality control product by the National Medical Products Administration [5]. - Dongya Pharmaceutical received approval for its fumaric acid valproate tablets from the National Medical Products Administration [5].